STOCK TITAN

Organigram Holdings Inc. - $OGI STOCK NEWS

Welcome to our dedicated page for Organigram Holdings news (Ticker: $OGI), a resource for investors and traders seeking the latest updates and insights on Organigram Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Organigram Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Organigram Holdings's position in the market.

Rhea-AI Summary
Organigram Holdings Inc. achieved positive cash flow and solidified its market position in Canada, announcing a $124.6 million strategic investment from BAT. They improved margins, maintained market positions, and introduced new products. Despite a decline in net revenue, the company showed positive Adjusted EBITDA and cash flow. Key financial metrics and balance sheet data highlight the company's financial standing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.55%
Tags
-
Rhea-AI Summary
Organigram Holdings Inc. (OGI) will report earnings for its first quarter fiscal 2024 on February 13, 2024. The conference call to discuss the results will be held at 8:00 am Eastern Time on the same day. The registration link for the call and webcast details are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
conferences earnings
-
Rhea-AI Summary
Organigram Holdings Inc. (OGI) has sent its first shipment of bulk dried flower to the medical division of German cannabis company, Sanity Group, as part of its multi-year agreement. The company will provide high-quality, indoor-grown dried flower product to Sanity Group and grant strain exclusivity on certain genetics. The inaugural shipment contains Organigram’s exceptional Super G Citra strain. This expansion into international markets reflects the company's commitment to quality, consistency, and consumer focus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
none
Rhea-AI Summary
Organigram Holdings Inc. (OGI) has closed the first tranche of a C$124,559,674 strategic equity investment by BT DE Investments Inc., a subsidiary of British American Tobacco plc. The Investor acquired 12,893,175 common shares at C$3.2203 per share, with the remaining shares to be issued in two further tranches. The investment will be used to create a strategic investment pool, named Jupiter, targeting emerging cannabis opportunities for geographic expansion. Organigram's 10 years of experience and successful cannabis investments position it for global growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
none
-
Rhea-AI Summary
Organigram Holdings Inc. appoints Karina Gehring to the Board of Directors, representing British American Tobacco plc. Gehring brings over 25 years of marketing and trade experience and is expected to provide valuable insights and expertise to the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.71%
Tags
management
-
Rhea-AI Summary
Organigram Holdings Inc. announced the results of its annual general and special meeting of shareholders, including the election of directors, committee composition, appointment of auditor, and shareholder approval of investment and articles of amendment. KPMG LLP was approved as the Company's auditor, and a C$124.6 million follow-on strategic equity investment was approved by the shareholders. The Investment is expected to close on or around January 23, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.71%
Tags
none
Rhea-AI Summary
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) announced a special meeting to approve a $124.6 million investment from BAT at $3.2203/share and the creation of the 'Jupiter' strategic investment pool. The investment is subject to approval by shareholders at the meeting to be held on January 18, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.09%
Tags
none
-
News
Rhea-AI Summary
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) announced its Fiscal 2023 results, including net revenue of $161.6 million, a 11% increase from the previous year, and an adjusted gross margin of $40.2 million, up 20% from the previous year. The company secured a $124.6 million private placement transaction with BAT-Jupiter, strengthened its market position, and achieved significant growth in several product categories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
-
Rhea-AI Summary
Organigram Holdings Inc. (OGI) has appointed Greg Guyatt as the new Chief Financial Officer, effective January 8, 2024. Mr. Guyatt brings over 25 years of international public company and private equity backed company experience to the role, replacing Paolo De Luca. The company aims to focus on ambitious growth plans and delivering bottom-line results under his leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
management
Rhea-AI Summary
Organigram Holdings Inc. (OGI) to Report Q4 and Fiscal 2023 Earnings Results on December 19, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
conferences earnings
Organigram Holdings Inc.

Nasdaq:OGI

OGI Rankings

OGI Stock Data

187.46M
68.41M
27.32%
8.8%
3.79%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
Toronto

About OGI

as part of canada’s marihuana for medical purposes regulations (mmpr), organigram (tsx-v:ogi) is atlantic canada's original licensed producer of medical marijuana. we are dedicated to consistently providing our clients with the highest quality, organically grown medicine and service. if you have questions or want to learn more, visit www.organigram.ca or give our client services team a call at 1-855-961-9420.